C4 Therapeutics Total Liab vs Common Stock Shares Outstanding

CCCC Stock

USD 2.65 0.14 5.02%

C4 Therapeutics financial indicator trend analysis is way more than just evaluating C4 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether C4 Therapeutics is a good investment. Please check the relationship between C4 Therapeutics Total Liab and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of C4 Therapeutics Total Liab account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have pay attention.

The correlation between C4 Therapeutics' Total Liab and Common Stock Shares Outstanding is -0.89. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of C4 Therapeutics, assuming nothing else is changed. The correlation between historical values of C4 Therapeutics' Total Liab and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of C4 Therapeutics are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Total Liab i.e., C4 Therapeutics' Total Liab and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.89

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Most indicators from C4 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into C4 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.92, whereas Selling General Administrative is forecasted to decline to about 27.4 M.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	7.6M	7.7M	8.9M	9.3M
Interest Income	3.6M	8.6M	9.9M	10.3M

Depreciation And Amortization Interest Income

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.82	0.84	0.96	1.0	-0.92	0.99	0.72	0.65	-0.21	-0.82	0.37	0.63	0.88	0.73	0.79	0.96	-0.83	0.86	-0.99	0.73	0.9	0.94	-0.98	1.0	0.74
Short Long Term Debt Total	0.82		0.94	0.8	0.81	-0.92	0.83	0.98	0.37	0.12	-0.93	-0.04	0.43	0.84	0.93	0.98	0.78	-0.72	0.82	-0.8	0.92	0.56	0.88	-0.8	0.8	0.99
Other Current Liab	0.84	0.94		0.87	0.83	-0.93	0.87	0.92	0.24	-0.17	-0.95	0.15	0.66	0.8	0.97	0.96	0.81	-0.8	0.91	-0.86	0.88	0.59	0.91	-0.86	0.83	0.93
Total Current Liabilities	0.96	0.8	0.87		0.96	-0.93	0.96	0.71	0.61	-0.33	-0.84	0.51	0.72	0.84	0.74	0.79	0.96	-0.94	0.96	-0.97	0.74	0.87	0.94	-0.96	0.96	0.73
Total Stockholder Equity	1.0	0.81	0.83	0.96		-0.91	1.0	0.71	0.64	-0.24	-0.81	0.39	0.65	0.86	0.72	0.78	0.97	-0.83	0.86	-0.99	0.71	0.9	0.93	-0.98	1.0	0.73
Other Liab	-0.92	-0.92	-0.93	-0.93	-0.91		-0.92	-0.87	-0.51	0.1	0.97	-0.2	-0.57	-0.89	-0.86	-0.9	-0.88	0.83	-0.9	0.93	-0.92	-0.76	-0.99	0.93	-0.91	-0.88
Net Tangible Assets	0.99	0.83	0.87	0.96	1.0	-0.92		0.74	0.58	-0.24	-0.83	0.36	0.67	0.86	0.76	0.81	0.96	-0.83	0.87	-0.99	0.72	0.87	0.93	-0.98	1.0	0.76
Property Plant And Equipment Net	0.72	0.98	0.92	0.71	0.71	-0.87	0.74		0.21	0.18	-0.91	-0.17	0.37	0.78	0.96	0.98	0.67	-0.63	0.76	-0.7	0.92	0.43	0.82	-0.71	0.7	1.0
Current Deferred Revenue	0.65	0.37	0.24	0.61	0.64	-0.51	0.58	0.21		0.05	-0.3	0.49	0.14	0.59	0.07	0.25	0.68	-0.59	0.48	-0.59	0.3	0.79	0.5	-0.57	0.65	0.24
Net Debt	-0.21	0.12	-0.17	-0.33	-0.24	0.1	-0.24	0.18	0.05		0.12	-0.7	-0.84	0.18	-0.02	0.1	-0.35	0.39	-0.34	0.35	0.06	-0.17	-0.23	0.36	-0.24	0.17
Retained Earnings	-0.82	-0.93	-0.95	-0.84	-0.81	0.97	-0.83	-0.91	-0.3	0.12		-0.08	-0.59	-0.79	-0.93	-0.92	-0.8	0.77	-0.87	0.85	-0.96	-0.58	-0.95	0.86	-0.81	-0.92
Accounts Payable	0.37	-0.04	0.15	0.51	0.39	-0.2	0.36	-0.17	0.49	-0.7	-0.08		0.62	0.14	-0.09	-0.07	0.5	-0.65	0.51	-0.44	-0.09	0.54	0.25	-0.4	0.39	-0.14
Cash	0.63	0.43	0.66	0.72	0.65	-0.57	0.67	0.37	0.14	-0.84	-0.59	0.62		0.29	0.52	0.44	0.73	-0.74	0.75	-0.74	0.42	0.45	0.66	-0.75	0.65	0.38
Non Current Assets Total	0.88	0.84	0.8	0.84	0.86	-0.89	0.86	0.78	0.59	0.18	-0.79	0.14	0.29		0.75	0.85	0.76	-0.7	0.76	-0.81	0.75	0.85	0.83	-0.8	0.86	0.81
Non Currrent Assets Other	0.73	0.93	0.97	0.74	0.72	-0.86	0.76	0.96	0.07	-0.02	-0.93	-0.09	0.52	0.75		0.98	0.66	-0.64	0.78	-0.73	0.89	0.44	0.84	-0.74	0.71	0.96
Other Assets	0.79	0.98	0.96	0.79	0.78	-0.9	0.81	0.98	0.25	0.1	-0.92	-0.07	0.44	0.85	0.98		0.72	-0.68	0.81	-0.77	0.9	0.54	0.86	-0.77	0.77	0.99
Cash And Short Term Investments	0.96	0.78	0.81	0.96	0.97	-0.88	0.96	0.67	0.68	-0.35	-0.8	0.5	0.73	0.76	0.66	0.72		-0.91	0.91	-0.98	0.69	0.84	0.91	-0.97	0.97	0.69
Net Receivables	-0.83	-0.72	-0.8	-0.94	-0.83	0.83	-0.83	-0.63	-0.59	0.39	0.77	-0.65	-0.74	-0.7	-0.64	-0.68	-0.91		-0.98	0.87	-0.66	-0.75	-0.83	0.85	-0.84	-0.65
Common Stock Shares Outstanding	0.86	0.82	0.91	0.96	0.86	-0.9	0.87	0.76	0.48	-0.34	-0.87	0.51	0.75	0.76	0.78	0.81	0.91	-0.98		-0.9	0.77	0.72	0.9	-0.89	0.86	0.77
Non Current Liabilities Total	-0.99	-0.8	-0.86	-0.97	-0.99	0.93	-0.99	-0.7	-0.59	0.35	0.85	-0.44	-0.74	-0.81	-0.73	-0.77	-0.98	0.87	-0.9		-0.74	-0.86	-0.95	1.0	-0.99	-0.72
Capital Lease Obligations	0.73	0.92	0.88	0.74	0.71	-0.92	0.72	0.92	0.3	0.06	-0.96	-0.09	0.42	0.75	0.89	0.9	0.69	-0.66	0.77	-0.74		0.47	0.9	-0.76	0.7	0.92
Other Current Assets	0.9	0.56	0.59	0.87	0.9	-0.76	0.87	0.43	0.79	-0.17	-0.58	0.54	0.45	0.85	0.44	0.54	0.84	-0.75	0.72	-0.86	0.47		0.76	-0.84	0.9	0.47
Other Stockholder Equity	0.94	0.88	0.91	0.94	0.93	-0.99	0.93	0.82	0.5	-0.23	-0.95	0.25	0.66	0.83	0.84	0.86	0.91	-0.83	0.9	-0.95	0.9	0.76		-0.96	0.92	0.83
Total Liab	-0.98	-0.8	-0.86	-0.96	-0.98	0.93	-0.98	-0.71	-0.57	0.36	0.86	-0.4	-0.75	-0.8	-0.74	-0.77	-0.97	0.85	-0.89	1.0	-0.76	-0.84	-0.96		-0.98	-0.73
Net Invested Capital	1.0	0.8	0.83	0.96	1.0	-0.91	1.0	0.7	0.65	-0.24	-0.81	0.39	0.65	0.86	0.71	0.77	0.97	-0.84	0.86	-0.99	0.7	0.9	0.92	-0.98		0.72
Property Plant And Equipment Gross	0.74	0.99	0.93	0.73	0.73	-0.88	0.76	1.0	0.24	0.17	-0.92	-0.14	0.38	0.81	0.96	0.99	0.69	-0.65	0.77	-0.72	0.92	0.47	0.83	-0.73	0.72

Click cells to compare fundamentals

High Positive Relationship

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

High Negative Relationship

Net Invested Capital	- 0.99	Non Current Liabilities Total
Non Current Liabilities Total	- 0.99	Net Tangible Assets
Other Stockholder Equity	- 0.99	Other Liab
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.99	Total Assets
Net Invested Capital	- 0.98	Total Liab

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	400.1M	506.8M	430.8M	376.5M	432.9M	362.8M
Short Long Term Debt Total	22.9M	42.9M	87.2M	71.0M	81.6M	46.2M
Other Current Liab	8.5M	12.3M	15.1M	20.6M	23.7M	12.1M
Total Current Liabilities	43.9M	51.2M	44.5M	42.8M	49.2M	44M
Total Stockholder Equity	280.8M	389.6M	289.2M	246.1M	283.0M	185.9M
Other Liab	72.7M	53.6M	24.4M	16.9M	15.2M	14.4M
Net Tangible Assets	(112.0M)	280.8M	389.6M	289.2M	332.6M	168.9M
Property Plant And Equipment Net	16.6M	35.1M	77.5M	71.1M	81.8M	43.9M
Current Deferred Revenue	27.6M	31.8M	33.5M	15.5M	17.8M	27.2M
Net Debt	(158.8M)	(33.2M)	57.4M	(55.6M)	(64.0M)	(67.2M)
Retained Earnings	(183.8M)	(267.7M)	(395.9M)	(528.4M)	(475.5M)	(451.8M)
Accounts Payable	5.7M	4.5M	1.2M	1.4M	1.3M	2.6M
Cash	181.7M	76.1M	29.8M	126.6M	145.6M	99.2M
Non Current Assets Total	19.1M	181.1M	143.3M	105.3M	121.1M	90.4M
Cash And Short Term Investments	371.7M	309.3M	337.1M	253.7M	291.7M	256.4M
Net Receivables	4.5M	5.7M	1.5M	11.8M	10.6M	15.3M
Common Stock Shares Outstanding	43.1M	46.0M	48.9M	49.6M	57.1M	45.0M
Liabilities And Stockholders Equity	400.1M	506.8M	430.8M	376.5M	432.9M	362.8M
Non Current Liabilities Total	75.5M	65.9M	97.1M	87.6M	78.8M	96.7M
Capital Lease Obligations	12.9M	32.1M	75.7M	71.0M	81.6M	85.7M
Other Current Assets	9.7M	21.4M	9.9M	5.7M	6.6M	9.0M
Other Stockholder Equity	464.6M	658.1M	689.3M	774.6M	890.8M	935.4M
Total Liab	119.3M	117.2M	141.6M	130.3M	117.3M	128.7M
Net Invested Capital	290.8M	400.4M	300.7M	246.1M	283.0M	191.8M
Property Plant And Equipment Gross	16.6M	42.0M	85.6M	//window.location = "/error404.html"; Updating Transaction... Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions Feedback Blog Made with optimal in San Francisco 2024 Macroaxis LLC COMMON DESTINATIONS My Portfolios Thematic Proposal Market Map Investment Tools Equity Filter ETFs Funds Companies Insiders Buy or Sell Advice Correlations Patterns Technical Analysis Risk-Return Landscape Investing Ideas Portfolio Center Financial Advisers Economic Indicators MAIN CATEGORIES Portfolio Optimization Equity Research Economic Indicators Watchlist Tools AI Investment Finder FinTech Suite Market Snapshot Latest Stories Investing Sectors AI Portfolio Architect Financial Widgets COMPANY Macroaxis Sign-In Home About Us Contact Us Quick Product Tour FAQs Privacy Policy Terms Of Use Plan & Pricing

CCCC Total Liab vs Common Stock Shares Outstanding Analysis

Total Liab vs Common Stock Shares Outstanding

Total Liab vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Total Liab

Common Stock Shares Outstanding

C4 Therapeutics fundamental ratios Correlations

C4 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

C4 Therapeutics fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY